Correction to: HIF prolyl hydroxylase inhibition protects skeletal muscle from eccentric contraction induced injury

Andrew N. Billin
Samuel E. Honeycutt
Alan V. McDougal
Jaclyn P. Kerr
Zhe Chen

See next page for additional authors
Correction to: HIF prolyl hydroxylase inhibition protects skeletal muscle from eccentric contraction induced injury

Andrew N. Billin1†, Samuel E. Honeycutt†, Alan V. McDougal1, Jaclyn P. Kerr1, Zhe Chen1, Johannes M. Freudenberg3, Deepak K. Rajpal3, Guizhen Luo1, Henning Fritz Kramer1, Robert S. Geske5, Frank Fang4, Bert Yao2, Richard V. Clark1, John Lepore2, Alex Cobitz2, Ram Miller1, Kazunori Nosaka5, Aaron C. Hinken1 and Alan J. Russell1*


Following publication of the original article [1], the authors flagged that there is a discrepancy with the Availability of data and materials statement on page 12 of the article.

This statement says that “Raw preclinical and clinical data for this manuscript will not be shared for logistical reasons.”

However, the authors state on page 10 of the article that “Anonymized individual participant data and study documents can be requested for further research from www.clinicalstudydatarequest.com.”

The policy at GlaxoSmithKline, Inc., the sponsor of this paper (see the Funding section on page 12), is consistent with the latter statement, of page 10. As such, in the interest of full transparency, please be advised that the Availability of data and materials statement on page 12 of the article is void.

Author details
1Muscle Metabolism Discovery Performance Unit, GlaxoSmithKline, King of Prussia, PA, USA. 2Metabolic Pathways and Cardiovascular Therapy Area, GlaxoSmithKline, King of Prussia, PA, USA. 3Target Sciences, GlaxoSmithKline, King of Prussia, PA, USA. 4Clinical Statistics, GlaxoSmithKline, King of Prussia, PA, USA. 5School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.

* Correspondence: arussell@edgewisetx.com
† Andrew N. Billin and Samuel E. Honeycutt contributed equally to this work.

Reference